367. Symptoms, neurocognition, and insight deficits in schizophrenia
- 作者T.E. Smith; J.W. Hull; D.F. Willson; L.M. Israel
- 卷第43卷
- 文件大小258.04KB
- 发表时间1998
- DOI10.1016/s0006-3223(98)90815-0
28-3 - Future antidepressants: What is possible?W.Z. Potter; M.A. Demitrack · 1997
Tissue localization of 7- and 8-hydroxychlorpromazinesR.P. Maickel; N.M. Fedynskyj; W.Z. Potter; A.A. Manian · 1974
Controlling the placebo response rates in depressionW.Z. Potter; M.A. Demitrack; D.J. DeBrota; D. Faries; J. Herrera · 1998
Effects of psychotropic drugs on neurotransmitters in manW.Z. Potter; M.V. Rudorfer; D. Pickar; M. Linnoila · 1987
82-3 - Hormones and antidepressants: implications for new drug developmentW.Z. Potter; D. Michelson · 1997
Promising medications not available in the United StatesI.D. Glick; O. Vinar; D.F. Klein; W.Z. Potter; S.A. Montgomery; Y. Lecrubier · 1994
324. Implications of a significant treatment by country interactionJ.D. Lightfoot; J.M. Herrera; R. Landin; D.J. Debrota; W. Offen; M.A. Demitrack; W.Z. Potter · 1998
S-25-5 - Clinical onset of antidepressant action: Implications for new drug developmentW.Z. Potter; H.K. Manji · 1996